The Lancet-EASL Commission is tackling liver diseases in Europe and overcoming unmet needs, stigma and inequities. The Commission is quantifying the burden of liver disease in Europe and addressing optimal diagnosis and standards of care for patients with liver diseases…
EASL, the European Association for the Study of the Liver, is now calling for nominations for a new Scientific Committee member to join the Governing Board for a 3 year term starting in April 2020. European National Associations are invited…
Call for schools 2021 EASL would like to provide its members with the ability to participate by opening a call for programme outline proposals and proposed topics. In 2021, EASL plans to present two clinical and one basic school, to…
Professor Paolo Angeli has been elected Editor-in-Chief of the Journal of Hepatology – the flagship journal of the European Association for the Study of the Liver (EASL) Prof. Paolo Angeli was selected by the EASL Governing Board, with his appointment…
Starting September 2019 Hainsworth will serve as the interface between the EASL Governing Board and the organisation`s Geneva and Brussels operations, ensuring high quality and effective implementation of the Governing Board`s policies and decisions. Hainsworth has worked for 25 years…
GENEVA, Switzerland Last week, ClarivateTM Analytics released the 2019 update of its Journal Citation Reports©, including the much anticipated 2018 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology achieved unprecedented results with a 2018 impact factor of 18.946,…
The General Assembly of the European Association for the Study of the Liver (EASL) has elected new members to its Governing Board, various committees and a new Editor-In-Chief for its Journal of Hepatology. 12 April 2019 - Vienna, Austria The…
According to a study conducted by the EF-Clif published in Gastroenterology This study has shown for the first time that the administration of albumin at high doses has an immunomodulatory effect both in the short (INFECIR-2) and long-term (Pilot-PRECIOSA) in…
Before the advent of antiretroviral drugs, the prognosis for patients with AIDS was extremely poor. However, new antiretroviral treatments have revolutionised care for patients with HIV/AIDS, making lifelong viral suppression possible and improving life expectancy to near normal in patients…
Liver cancer is a leading cause of cancer death, with hepatocellular carcinoma (HCC) accounting for 85–90% of all primary liver cancers. In a recent issue of Journal of Hepatology, Dr Baumeister et al. showed that higher total physical activity was…